Patients may not be receiving investigational agents at time of registration, or at any time while on study and during the  weeks preceding enrollment
Use of any other investigational or study agents
Use of investigational cancer agents within  weeks prior to diagnosis
Patients must not receive any other investigational agents while on study or within four weeks prior to registration
Other anticancer agents and investigational agents should not be given while the subject is on study treatment
Investigational agents from previous clinical study within  weeks
Participants cannot receive treatment with any other investigational agents during protocol therapy
No chemotherapy, other investigational agents within  days of study treatment
Exposure to any other anti-leukemic therapy (except hydroxyurea) within  weeks before the first dose of study treatment (including investigational chemotherapy regimens involving approved agents)
Patients must not have ongoing treatment with any other investigational agents =<  days prior to registration
Participant has used investigational agents within  weeks of randomization.
Prior treatment with FR-targeting investigational agents is not allowed
Any investigational agents or drugs from a previous clinical study within  days
Patients who are receiving any other investigational agents, with the exception of virus-specific cytotoxic T-cells for the treatment of viral infection/reactivation prior to allo BMT
Other investigational agents: ? weeks
No use of investigational agents within  weeks of study enrollment or use of immunosuppressive or immunomodulating agents within  weeks of study entry
Prior treatment with folate receptor (FR) targeting investigational agents is allowed for dose escalation provided that such treatment was not discontinued due to adverse events; prior FR-targeting investigational agents are not allowed for patients in the expansion cohort
Treatment with any investigational antileukemic agents or chemotherapy agents in the last  days before study entry, unless full recovery from side effects has occurred or patient has rapidly progressive disease judged to be life-threatening by the investigator
Use of any chemotherapy, investigational agents, immunotherapy, or hormonal therapy other than GnRH agonists within  days of the start of treatment on protocol. Use of bone targeted agents including bisphosphonates and RANK ligand inhibitors is allowed if on stable dose; Xgeva or Zometa cannot be started within  days of initiating study therapy.
Participants who received investigational agents, other than investigational antiretroviral agents for HIV, within the  weeks before randomization, unless approved by the study chair
Use of any other investigational agents within  days of starting study treatment
Prior BCMA-directed investigational agents at any time
Treatment with any investigational antileukemic agents or chemotherapy agents in the last  days before study entry, unless full recovery from side effects has occurred or patient has rapidly progressive disease judged to be life-threatening by the investigator.
Use of immune suppressive agents within  days
Treatment with any investigational antileukemic agents or chemotherapy agents in the last  days before study entry, unless full recovery from side effects has occurred or patient has rapidly progressive disease judged to be life-threatening by the investigator.
Patients may not be receiving any other investigational agents; a  week wash-out period for investigational agents is required before registration
No investigational agents within  weeks prior to first study treatment.
Subjects must not have had any prior investigational agents or devices within  weeks of beginning study drug
Patients are permitted to receive investigational imaging agents while on study
Use of any investigational agents within  days of registration.
Use of any of the following after transplantation and prior to starting study therapy for cohort :\r\n* Investigational agents/therapies\r\n* Anti-leukemic agents given as post-transplant maintenance therapy (e.g., subcutaneous or oral -azacytidine or FLT inhibitors for maintenance)
Use of any active treatment for relapse/refractory AML including but not restricted to chemotherapy, targeted agents, hypomethylating agents or investigational drugs; use of hydroxyurea up to g per day for cytoreduction is allowed for a maximum of  days prior treatment
Participation in any other investigational study or use of any other investigational agents within  days prior to study entry
Patients may not be receiving any other investigational agents, chemotherapy, immunotherapy, radiotherapy, or molecular targeted agents within  weeks of the start of the study treatment.
At least  weeks must have passed since any of the following: systemic corticosteroids, immunotherapy (for example, T-cell infusions, immunomodulatory agents, interleukins, MCC vaccines, intravenous immunoglobulin, expanded polyclonal tumor infiltrating lymphocytes [TIL] or lymphokine-activated killer [LAK] therapy), pentoxifylline, other small molecule or chemotherapy cancer treatment, other investigational agents or other systemic agents that target Merkel cell carcinoma
Subjects requiring or using other investigational agents while on treatment in this trial.
Use of any investigational agents within  days prior to enrollment and for the duration of the study
Chemotherapeutic agents for therapy of AML (note that prophylactic use of these agents is allowed in this study, e.g., methotrexate for GVHD)
Investigational agents/therapies
Patients may not be receiving any other investigational agents with the intent to treat the disease (imaging agents are acceptable)
Treatment with chemotherapy, monoclonal antibodies or biological agents (e.g. lenalidomide) other than the investigational agents during the time of participation in this trial
Investigational compound within  weeks of enrollment or who are planning to receive other investigational agents while participating in this study
Ongoing use of investigational agents or use of investigational agents within the last four weeks
Are being treated with other investigational agents.
Treatment with any investigational antileukemic agents or chemotherapy agents in the last  days before study entry, unless full recovery from side effects has occurred or patient has rapidly progressive disease judged to be life-threatening by the investigator
-  Investigational Agents: Investigational agents within  weeks (or  half-lives) of PV- administration.
Prior or current use of any investigational or commercially available anti-HCV agents other than interferon or ribavirin or receipt of any investigational product within  weeks prior to study drug administration
Previous treatment with any other investigational agents within  weeks prior to MCLA- administration;
No use of investigational agents within  weeks of study enrollment or use of immunosuppressive or immunomodulating agents (including intravenous immunoglobulin [IVIG]) within  weeks of study entry; note: use of topical, inhaled and intranasal steroid therapy is permitted
No non-approved investigational agents or procedures ? weeks of study entry
Prior treatment with non-chemotherapy investigational agents is permitted
Use of other investigational agents within  months prior to enrollment
Receiving any other investigational agents within  weeks of beginning study treatment
No investigational agents within  weeks from initiation of study treatment
Patients must not receive any other investigational agents while on study or within four weeks prior to randomization
Use of any investigational agent within the last  days. For classes of investigational agents that are not known to have prolonged toxicities the wash-out time may be decreased to  days after agreement with the Medical Monitor.
Any other investigational agents within the past  weeks
Patients may not be receiving any other investigational agents with the intention to treat their cancer (imaging trials are acceptable)
Ongoing use of any other investigational or study agents
Patients may not be receiving any other investigational agents within  weeks of starting the study treatment and during the study period
Patients must not receive any other investigational agents during the period on study or the four weeks prior to entry
Patients may not be receiving any other investigational agents at time of study entry or at any time while on study or be on another investigational agent that can impact on the primary clinical outcome analyses or has known pharmacodynamics or pharmacokinetic effects on AAT
Treatment with other investigational agents
Patients must not be planning to receive any other investigational agents during the course of protocol treatment
Use of T-cell depleting agents
Active treatment with any other investigational agents
Patients may not be planning to receive any other investigational agents
Use of cytotoxic, chemotherapeutic, targeted or investigational agents/therapies, thrombopoiesis-stimulating agents (TSAs), erythropoiesis-stimulating agents (ESAs) and other red blood cell hematopoietic growth factors, and within  days prior to randomization
Patients must not have used cytotoxic chemotherapeutic agents or experimental agents (agents that are not commercially available) for the treatment of MDS within  weeks of randomization
Other investigational agents/therapy with the intention to treat the disease under study (observational or imaging trials are acceptable)
Other investigational agents within  days prior to study treatment.
Use of any other investigational agents
Use of investigational agents within  days
Concurrent usage of other investigational agents, chemotherapy, or hormone therapy; prior chemotherapy, hormonal therapy, targeted therapy, and investigational agents are allowed but all toxicities grade >=  must have resolved by the time of study commencement (except alopecia)
Patients may not be receiving any other investigational agents\r\n* Note: a wash-out period of  weeks prior to registration is required for any patient to be enrolled in the study
Patients must be off all other anti-tumor therapies (including immunologic agents) for at least four weeks prior to study registration. Patients on hormonal agents require a washout for  days.
No other non-protocol antineoplastic agents will be permitted during this study
Use of any other investigational agents
Prior investigational agents =<  weeks prior to registration
Previous treatment with a camptothecin derivative (eg., irinotecan, topotecan, and investigational agents including but not limited to exatecan, rubitecan, gimatecan, karenitecan, SN investigational agents, EZN , SN , and AR ) is not allowed
Treatment with chemotherapy, monoclonal antibodies, biological agents (e.g. Ibrutinib) or other than the investigational agents during the time of participation in this trial
Other investigational agents =<  weeks prior to registration/ randomization
At least  weeks since prior biologics or investigational agents
Prior use of other investigational agents to treat the brain tumor
Other investigational agents/therapy with the intention to treat the disease under study (observational or imaging trials are acceptable)
Prior chemotherapy, cancer immunosuppressive therapy, or other investigational agents within  weeks before first dose of study drug.
Treatment with other investigational agents =<  days of registration
Participants may not be receiving any other investigational or commercial agents or therapies other than those described in this protocol to treat their malignancy
Use of cytotoxic chemotherapeutic agents, or experimental agents (agents that are not commercially available) for the treatment of CMML within  days of the first day of study drug treatment
Exposure to chemotherapy, radiotherapy, biologics or investigational agents within  weeks prior enrollment in the study
Treatment with other investigational agents in the prior  weeks.
Use of investigational agents within  weeks prior to enrollment
Any investigational agents
Treatment with any investigational antileukemic agents or chemotherapy agents in the last  days before study entry, unless full recovery from side effects has occurred or patient has rapidly progressive disease judged to be life-threatening by the investigator
Immunomodulatory agents within  days
Patients who are receiving any other investigational agents or commercial agents with the intent to treat the malignancy
Other investigational agents: ? weeks
Treatment with other investigational agents within the prior  days prior to the st dose of AbGn-H (neihulizumab)
Patient should not be part of another trial testing other investigational agents or devices
Patients must have discontinued immunotherapy or other systemic therapy including investigational agents at least  weeks prior to entering the study and have recovered from adverse events due to those agents. Patients must agree to not receive any other investigational agents during study participation.
Patients may not receive any other anti-neoplastic or investigational agents within  weeks of study enrollment; patients may not be receiving any other investigational agents during treatment on protocol
Administration of any investigational agents within  days before study entry
Prior anti-leukemia therapy within  days of enrollment for classical cytotoxic agents, and within x the half-life for other investigational agents
Receiving any other investigational agents simultaneously or within  weeks following ablation procedure
Use of investigational device or agents within  weeks of enrollment date.
Investigational agents/therapies
Investigational agents within  weeks of randomization.
Use of other investigational agents within  weeks of day  of protocol therapy
Treatment less than two weeks prior to enrollment with other systemic experimental therapies or antineoplastic agents, with the exception of hydroxyurea and intrathecal chemotherapeutic agents
Patients who are receiving any androgens, estrogens or progestational agents, or who received any of these agents within the  months prior to evaluation will not be eligible
Investigational agents within  weeks of initial study treatment.
Other investigational agents/therapy with the intention to treat the disease under study (observational or imaging trials are acceptable)
Other investigational agents/therapy with the intention to treat the disease under study (observational or imaging trials are acceptable)
Patients may not use any of the following therapies during the study:\r\n* Any non-study anti-cancer agent (investigational or non-investigational)\r\n* Any other investigational agents\r\n* Any other (non-CA related) CTLA- inhibitors or agonists\r\n* CD agonists\r\n* Immunosuppressive agents\r\n* Chronic systemic corticosteroids\r\n* Any non-oncology vaccine therapies used for the prevention of infectious diseases (for up to  days prior to or after any dose of study drug)
Use of investigational agents, with the exception of gemtuzumab ozogamicin, within  days
Systemic anticancer treatment (including investigational agents) or radiotherapy less than  weeks before the first dose of study treatment (<= weeks for large molecule agents).
No restrictions on use of other investigational agents
Participants who are receiving any other investigational agents within  weeks prior to enrollment; investigational antiretroviral agents for HIV are acceptable
No restrictions regarding use of other investigational agents
Subjects must agree to not use any other topical agents on skin in the radiation treatment area during the course of this trial; subjects should only use topical agents for the study (i.e., topical intervention or standard care agents) supplied by the study personnel and/or treating physician
GENERAL EXCLUSION CRITERIA FOR SUBPROTOCOLS: Concomitant medications\r\n* Corticosteroids: at the time of consent and enrollment to regimen specific subprotocols, patients receiving corticosteroids who have not been on a stable or decreasing dose of corticosteroid for at least  days prior to enrollment to the subprotocol will not be eligible; if used to modify immune adverse events related to prior therapy, >=  days must have elapsed since last dose of corticosteroid\r\n* Investigational drugs: patients must meet criteria for prior therapy at the time of consent and enrollment to a subprotocol; other investigational agents may not be administered to patients while they are receiving study drug as part of a subprotocol \r\n* Anticancer agents: patients must meet criteria for prior therapy at the time of consent and enrollment to a subprotocol; other investigational agents may not be administered to patients while they are receiving study drug as part of a subprotocol \r\n* Anti-GVHD agents post-transplant: patients who are receiving cyclosporine, tacrolimus or other agents to prevent graft-versus-host disease post bone marrow transplant are not eligible
Participants who received any other chronic (defined as more than % of the time in the last  months) systemic immunomodulatory agents (replacement doses of steroids for adrenal insufficiency are permitted or treatment with prednisone =<  mg/day); receipt of investigational agents within the  weeks before randomization enrollment, other than investigational antiretroviral agents for HIV and investigational or approved agents for hepatitis C, are also exclusionary
Use of any other investigational agents =<  weeks prior to pre-registration
Active use of any other investigational agents
Receipt of any other investigational agents =<  months prior to randomization, except innocuous agents with no known interaction with the study agents (e.g., standard dose multivitamins or topical agents for limited skin conditions), at the discretion of the protocol lead investigator at each participating site
Receiving any other investigational agent =<  months prior to registration/randomization, except innocuous agents with no known interaction with the study agent (e.g., standard dose multivitamins or topical agents for limited skin conditions)
Ongoing therapy with other investigational agents
Participants may not receive any other investigational agents within  days of enrollment nor during study participation
There will be no restrictions regarding use of other investigational agents
There will be no restrictions regarding use of other investigational agents
Other on-going cancer therapy or investigational agents (except MVT- )
Patients must not receive any other investigational agents while on study
Patients should not be taking other investigational agents
Subject has had no use of investigational agents, with the exception of FLT inhibiting agents during induction and/or consolidation therapy, within the prior  weeks.
Patients should not be taking other investigational agents
At the time of registration, all subjects must be removed >=  days from any investigational agents
Ongoing treatment with any other investigational agents
Treatment with other investigational agents less than  days prior to study entry.
